We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-2.94%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$339M
(-18%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-18.81%
Top 10 Holdings %
Top 10 Hldgs %
41.55%
Holding
80
New
12
Increased
20
Reduced
21
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$51M |
| 2 |
Natera
NTRA
|
+$41.9M |
| 3 |
Becton Dickinson
BDX
|
+$37.3M |
| 4 |
Cytokinetics
CYTK
|
+$37M |
| 5 |
Abbott
ABT
|
+$35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$158M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$85.6M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$49.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$47.9M |
| 5 |
Tenet Healthcare
THC
|
+$40.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.96% |
| 2 | Consumer Discretionary | 1.59% |
| 3 | Financials | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30.7B
| $84.6M | 5.64% |
401,660
-51,740
| -11% | -$11.3M |
|
2
Boston Scientific
BSX
$68.4B
| $82M | 5.47% |
1,850,450
+586,780
| +46% | +$25.4M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $74.7M | 4.98% |
710,110
-122,160
| -15% | -$11.9M |
|
|
4
BioMarin Pharmaceuticals
BMRN
$11.7B
| $59.3M | 3.96% |
769,016
+609,696
| +383% | +$51M |
|
|
5
Natera
NTRA
$38.6B
| $59M | 3.93% |
1,449,536
+696,616
| +93% | +$41.9M |
|
|
6
Abbott
ABT
$183B
| $57.4M | 3.83% |
484,740
+282,030
| +139% | +$35M |
|
7
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $53.9M | 3.6% |
+600,000
| New | +$55.4M |
|
8
Centene
CNC
$30.1B
| $53.4M | 3.56% |
634,610
-115,660
| -15% | -$9.49M |
|
9
Cencora
COR
$60.7B
| $51.2M | 3.42% |
330,910
-190,010
| -36% | -$26.9M |
|
10
Humana
HUM
$44B
| $47.5M | 3.17% |
109,040
+54,400
| +100% | +$22.8M |
|
11
Cooper Companies
COO
$14.2B
| $45.3M | 3.02% |
434,360
+113,840
| +36% | +$11.5M |
|
12
Envista
NVST
$4.52B
| $44.5M | 2.97% |
914,490
-728,190
| -44% | -$33.6M |
|
|
13
Cytokinetics
CYTK
$10.9B
| $41.8M | 2.79% |
1,135,110
+1,040,990
| +1,106% | +$37M |
|
14
AbbVie
ABBV
$455B
| $41.2M | 2.75% |
254,160
+129,010
| +103% | +$18.7M |
|
15
LivaNova
LIVN
$4.45B
| $41.1M | 2.74% |
502,350
+71,750
| +17% | +$5.58M |
|
16
Incyte
INCY
$24.9B
| $39.7M | 2.65% |
500,400
+392,350
| +363% | +$28.5M |
|
|
17
Bristol-Myers Squibb
BMY
$132B
| $38.7M | 2.58% |
530,160
-1,274,390
| -71% | -$85.6M |
|
|
18
Becton Dickinson
BDX
$45.6B
| $37.6M | 2.51% |
+144,997
| New | +$37.3M |
|
19
UnitedHealth
UNH
$383B
| $37M | 2.47% |
72,580
+43,580
| +150% | +$21M |
|
20
Elevance Health
ELV
$81.6B
| $36M | 2.4% |
73,350
-28,210
| -28% | -$12.9M |
|
21
Teleflex
TFX
$5.86B
| $35.2M | 2.35% |
+99,150
| New | +$32.6M |
|
22
Universal Health Services
UHS
$9.88B
| $33.1M | 2.21% |
228,410
-57,210
| -20% | -$7.91M |
|
23
McKesson
MCK
$101B
| $29.3M | 1.96% |
95,800
+31,730
| +50% | +$8.63M |
|
24
CVS Health
CVS
$134B
| $29M | 1.94% |
+286,600
| New | +$30.1M |
|
25
Danaher
DHR
$138B
| $28.6M | 1.91% |
109,969
-59,897
| -35% | -$15M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2022 Portfolio in Review
As of Q1 2022, HealthCor Management held 80 positions worth $1.5B, down 18% from $1.84B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
HealthCor Management withdrew a net $282M in Q1 2022, closing 16 positions and reducing 21 holdings. Its most notable exit was Medtronic, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, HealthCor Management opened a new position in Becton Dickinson worth $37.6M.
- HealthCor Management's largest Q1 2022 buy was Becton Dickinson: 144,997 shares worth $37.6M.
- HealthCor Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $51M increase.
- HealthCor Management's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $85.6M.
- HealthCor Management fully exited Medtronic in Q1 2022, selling an estimated $158M.
- HealthCor Management's ten largest holdings make up 42% of its $1.5B portfolio in Q1 2022.
- HealthCor Management opened 12 new positions and closed 16 in Q1 2022.
- HealthCor Management's portfolio value fell 18% quarter-over-quarter to $1.5B.
Based on HealthCor Management's 13F filing for Q1 2022, filed 16 May 2022.